1. Home
  2. NRT vs FGEN Comparison

NRT vs FGEN Comparison

Compare NRT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

HOLD

Current Price

$6.25

Market Cap

57.0M

Sector

Energy

ML Signal

HOLD

Logo FibroGen Inc

FGEN

FibroGen Inc

HOLD

Current Price

$8.41

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRT
FGEN
Founded
1975
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.0M
35.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NRT
FGEN
Price
$6.25
$8.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$146.50
AVG Volume (30 Days)
63.6K
28.8K
Earning Date
12-30-2025
11-10-2025
Dividend Yield
12.90%
N/A
EPS Growth
24.05
N/A
EPS
0.59
53.38
Revenue
$6,184,173.00
$8,298,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.59
$0.16
Revenue Growth
18.55
N/A
52 Week Low
$3.88
$4.85
52 Week High
$6.95
$21.94

Technical Indicators

Market Signals
Indicator
NRT
FGEN
Relative Strength Index (RSI) 55.76 38.23
Support Level $6.10 $7.99
Resistance Level $6.61 $9.09
Average True Range (ATR) 0.26 0.37
MACD 0.00 0.10
Stochastic Oscillator 66.25 34.82

Price Performance

Historical Comparison
NRT
FGEN

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Share on Social Networks: